TAS-102 and Bevacizumab as salvage line chemotherapy for colorectal cancer
- Conditions
- Colorectal Cancer
- Registration Number
- JPRN-UMIN000031790
- Lead Sponsor
- Surgical Oncology Association in Chiba (SOAC)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 45
Not provided
1)contraindications for TAS-102 and BEvacizumab 2)previously received chemotherapy with TAS-102 3)severe drug allergy 4)pregnant woman or Possibility of the pregnant woman. male patient who hoping partner's pregnancy. 5)patient who has important clinical complications(symptomatic unstable ischemic heart disease, arrhythmia, acute myocardial infarction within 6 months, liver cirrhosis, renal failure, active gastrointestinal ulcer, ileus, uncontrolled diabetes, uncontrolled hypertension, etc.) 6)have pleural effusion and ascitic fluid with the treatment 7)previous hemoptysis (over 25ml of fresh blood) 8)current or previous (within the last 6 months) history of GI perforation 9)patient with thrombosis (within the last 6 months) 10)patient with bleeding tendency 11)synchronous or metachronous multiple malignancy within the last 5 year disease free interval 12)dicision of unsuitable for this study by the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression Free Survival
- Secondary Outcome Measures
Name Time Method 1)Overall Survival 2)Time to Treatment Failure 3)Response Rate 4)Disease control rate 5)Adverse events 6)Relation between RAS status and effectiveness of chemotherapy 7)Relation between location of tumor and effectiveness of chemotherapy 8)Relation between the timing when chemotherapy started and effectiveness of chemotherapy